OakChart

Ovid Therapeutics Inc

OVIDHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 9:52 AM ET

2.82+0.02 (0.54%)
2026-11-11 15:53 CET
Market cap
546.83 USD m
Revenue, TTM
1.45 USD m
Net income, TTM
-43.11 USD m
Free cash flow, TTM
-57.78 USD m
EPS diluted, TTM
-0.18
P/E
-
Compare

Price

OVID against its 20, 50 and 200-day averages
2050200beatmissearnings
2.002.503.0011.3M22.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OVIDclose 2.8220-day 2.4750-day 2.52200-day 2.402.82

9.3% under 3.11 on 9 Apr 2026. Last 15 sessions, 47.1% high to low

Profile

OVID
52-week range, 85% of the way up
1.183.11

Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.

IndexRUT
Employees23
IPOMay 05, 2017
Beta0.23
ATR, 14d0.21
Rel volume0.51
Short float10.03%
Insider own7.38%
Inst own79.89%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap549.76M
Enterprise Value425.51M
Income-43.11M
Sales1.45M
Book/sh1.05
Cash/sh0.70
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees23
IPOMay 05, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S379.14
P/B2.67
P/C4.02
P/FCF-
EV/EBITDA-
EV/Sales293.45
Quick Ratio11.97
Current Ratio11.97
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.18
EPS next Y-0.42
EPS next Q-0.10
EPS this Y-69.90%
EPS next Y-8.66%
EPS next 5Y-23.93%
EPS past 3/5Y32.53% 29.81%
Sales past 3/5Y68.99% -10.48%
EPS Y/Y TTM63.85%
Sales Y/Y TTM-78.05%
EPS Q/Q40.12%
Sales Q/Q-100.00%
EarningsNov 10 BMO
EPS/Sales Surpr.-18.06% -100.00%

Ownership

Insider Own7.38%
Insider Trans0.00%
Inst Own79.89%
Inst Trans26.98%
ROA-30.14%
ROE-35.43%
ROIC-20.58%
Gross Margin92.42%
Oper. Margin-4700.28%
Profit Margin-2971.26%
SMA2014.13%
SMA5011.88%
SMA20017.11%
Trades-

Technical

Shs Outstand188.72M
Shs Float180.88M
Short Float10.03%
Short Ratio9.72
Short Interest18.13M
52W High3.11 -9.34%
52W Low1.18 138.56%
Volatility12.23% 9.50%
ATR (14)0.21
RSI (14)60.72
Beta0.23
Rel Volume0.51
Avg Volume1.87M
Volume101,834

Performance

Perf Week2.74%
Perf Month28.54%
Perf Quarter0.54%
Perf Half Y0.54%
Perf YTD72.70%
Perf Year108.52%
Perf 3Y-13.38%
Perf 5Y-19.80%
Perf 10Y-
Recom1.00
Target Price6.40
Prev Close2.80
Price2.82
Change %0.54%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedWWolfe ResearchOutperform$5+77.6%
Oct 09, 2026InitiatedCCantor FitzgeraldOverweight
Oct 06, 2026InitiatedGGuggenheimBuy$7+148.7%
Dec 11, 2025InitiatedRRoth CapitalBuy$3+6.6%
Nov 17, 2025InitiatedLLeerink PartnersOutperform
Oct 09, 2025InitiatedOOppenheimerOutperform$7+148.7%
Aug 08, 2025ResumedRB. Riley SecuritiesBuy$3+6.6%
Jun 18, 2024DowngradeOOppenheimerOutperform → Perform
Apr 30, 2024InitiatedRB. Riley SecuritiesBuy$9+219.7%
Apr 29, 2024InitiatedHH.C. WainwrightBuy$9+219.7%

Peers

Mkt cap
TickerCompanyMkt cap
XENEXenon Pharmaceuticals Inc4.10B
STOKStoke Therapeutics Inc1.77B
RAPPRapport Therapeutics Inc1.57B
PRAXPraxis Precision Medicines Inc9.65B
NGNENeurogene Inc518.46M
MPLTMapLight Therapeutics Inc416.81M
CTNMContineum Therapeutics Inc424.47M
ACADAcadia Pharmaceuticals Inc3.15B
NERVMinerva Neurosciences Inc124.09M
TSHATaysha Gene Therapies Inc1.40B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Jeffrey A. RonaAffiliated StockholderAug 24 '26Proposed Sale2.80325,000910,000Aug 24 04:47 PM
Jeffrey A. RonaAffiliated StockholderAug 14 '26Proposed Sale2.80150,000420,000Aug 14 06:27 PM
LEVIN JEREMY MExecutive ChairmanMar 23 '26Option Exercise1.4047,33366,2663,735,048Mar 25 09:18 PM
ALEXANDER MARGARET A.President and CEOFeb 23 '26Sale1.4511,65616,90161,750Mar 02 04:30 PM
Rona Jeffrey ACBFOFeb 23 '26Sale1.458,54112,38488,188Mar 02 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWCiShares Micro-Cap ETFAUM: 1.22B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 206
  • VC funding in Europe falls short at early-stage investment hurdles (Pharmaceutical Technology)
  • Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results (GlobeNewswire)
  • Ovid Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.84%
  • Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer (PR Newswire)
  • Ovid Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Loading…
  • Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results (GlobeNewswire) +6.87%
  • Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development (GlobeNewswire)
  • Ovid Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors (GlobeNewswire)
  • Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results (GlobeNewswire)
  • Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 (GlobeNewswire)
  • Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +14.43%
  • Ovid Therapeutics Announces Pricing of $60 Million Private Placement (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.100-0.085-0.1000.000.0313
2026Q22026-08-13-0.080-0.115-0.0760.730.0210
2026Q12026-05-12-0.120-0.124-0.1250.000.069
2025Q42026-03-180.060-0.1170.1180.720.0810
2025Q32025-11-12-0.170-0.150-0.1710.130.198
2025Q22025-08-13-0.060-0.158-0.0666.270.107
2025Q12025-05-13-0.140-0.138-0.1440.130.056
2024Q42025-03-11-0.130-0.169-0.1300.080.199
2024Q32024-11-12-0.200-0.207-0.1970.170.119
2024Q22024-08-130.120-0.2240.1200.170.0710
2024Q12024-05-14-0.170-0.224-0.1650.150.059
2023Q42024-03-08-0.220-0.051-0.2170.148.627
2023Q32023-11-03-0.160-0.185-0.1590.110.056
2023Q22023-08-04-0.180-0.204-0.1760.080.055
2023Q12023-05-05-0.190-0.171-0.1900.070.024
2022Q42023-03-13-0.160-0.172-0.1630.050.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.540-1.624-1.5420.000.00
2020FY-1.390-1.349-1.38612.6211.08
2021FY1.7602.0181.776208.38208.39
2022FY-0.770-0.752-0.7691.501.47
2023FY-0.740-0.576-0.7420.398.79
2024FY-0.370-0.465-0.3730.570.66
2025FY-0.230-0.477-0.2307.256.60
2026FY--0.387--0.78
2027FY--0.418--0.46
2028FY--0.438--17.80
2029FY--0.424--16.34
2030FY--0.178--59.93

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-1011100.090.000.72
2026Q4S2026-10-2711000.090.000.72
2026Q4S2026-10-1411010.090.000.72
2026Q4S2026-10-0810010.100.000.72
2026Q4S2026-10-029010.110.000.72
2026Q4S2026-09-108010.100.000.72
2026Q4S2026-09-027010.110.000.72
2026Q4S2026-08-306010.130.000.72
2026Q4S2026-08-217010.110.000.72
2026Q4S2026-08-138010.100.000.72
2026Q4S2026-08-058000.110.000.72
2026Q4S2026-06-018010.110.000.72
2026Q4S2026-05-228110.110.000.72
2026Q4S2026-05-128110.130.000.72

Estimate history

EPS, annual-3.35-2.11-1.542-1.3861.776-0.769-0.742-0.373-0.236-0.1848
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.197-0.13-0.144-0.066-0.1710.118-0.125-0.076-0.102
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00012.617208.3831.5030.3920.5667.2521.45
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1730.0760.136.2720.1320.71800.7330
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual24.60624.65454.7165.74370.36570.46770.69271.01130.184188.721
Period201720182019202020212022202320242025MRQ
Shares, quarterly71.0171.0171.1171.1171.152130.184167.266184.756188.721
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.457.250.570.391.50208.3812.620.000.00
Cost of Goods Sold Incl. D&A0.110.300.601.601.38--0.260.14
Gross Profit1.346.95-0.03-1.200.12---0.26-0.14
Selling, General and Administrative Excl. Other69.5449.3961.8558.0855.6783.9493.7461.1552.79
Research and Development43.3225.3836.3728.1724.3046.8663.3642.1233.79
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-68.20-42.44-61.88-59.28-55.55124.21-81.43-61.41-52.93
Interest Expense0.000.000.00-0.000.000.000.000.00
Unusual Expense-21.051.300.800.500.000.00--
Net Income Before Taxes-43.11-17.41-26.43-52.34-54.17124.16-81.04-60.46-51.98
Income Taxes0.000.000.000.000.001.330.000.000.00
Consolidated Net Income-43.11-17.41-26.43-52.34-54.17119.84-81.04-60.46-51.98
Net Income From Continuing Operations-43.11-17.41-26.43-52.34-54.17119.84-81.04-60.46-51.98
Net Income-43.11-17.41-26.43-52.34-54.17119.84-81.04-60.46-51.98
EPS (Recurring)-0.21-0.04-0.36-0.73-0.761.76-1.39-1.54-2.11
EPS (Basic, Before Extraordinaries)-0.18-0.24-0.37-0.74-0.771.78-1.39-1.54-2.11
EPS (Diluted)-0.18-0.24-0.37-0.74-0.771.78-1.39-1.54-2.11
EBITDA-68.09-42.14-61.28-57.68-54.17124.45-81.12-61.15-52.79
Non-Operating Income (Expense)46.0746.0836.757.741.88-0.050.400.950.95
Other After Tax Adjustments0.000.000.000.000.00-3.000.000.000.00
Stock Option Compensation Expense4.954.814.965.765.183.697.535.217.06
Price To Earnings Ratio-----1.82---
Price To Sales Ratio348.4016.57116.97580.2287.171.0510.70--
Gross Margin92.4295.86-6.01-307.618.06----
Operating Margin-4,700.28-585.20-10,933.75-15,134.60-3,696.4459.61-645.40--
Net Margin-2,971.26-240.13-4,670.14-13,362.17-3,604.6657.51-642.26--
Shares Outstanding188.72130.1871.0170.6970.4770.3665.7454.7124.65
Market Capitalization546.83546.8366.30227.59131.07218.58146.54198.4459.66

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.730.000.720.136.270.130.08
Cost of Goods Sold Incl. D&A0.010.020.040.040.020.100.140.15
Gross Profit-0.010.72-0.040.670.126.17-0.01-0.07
Selling, General and Administrative Excl. Other22.3516.4117.8112.9712.6411.2512.5410.65
Research and Development15.689.9411.156.555.856.406.575.83
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.36-15.70-17.85-12.29-12.52-5.07-12.55-10.72
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense---20.990.000.000.074.80
Net Income Before Taxes-20.78-15.01-16.999.66-12.16-4.68-10.23-9.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-20.78-15.01-16.999.66-12.16-4.68-10.23-9.25
Net Income From Continuing Operations-20.78-15.01-16.999.66-12.16-4.68-10.23-9.25
Net Income-20.78-15.01-16.999.66-12.16-4.68-10.23-9.25
EPS (Recurring)-0.10-0.08-0.120.30-0.17-0.07-0.14-0.08
EPS (Basic, Before Extraordinaries)-0.10-0.08-0.120.12-0.17-0.07-0.14-0.13
EPS (Diluted)-0.10-0.08-0.120.12-0.17-0.07-0.14-0.13
EBITDA-22.35-15.68-17.81-12.25-12.51-4.97-12.41-10.57
Non-Operating Income (Expense)1.580.690.8642.940.360.392.386.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.281.431.051.201.111.221.281.00
Price To Sales Ratio348.40335.5342.4518.3613.993.5340.44117.14
Gross Margin-97.82-93.8787.1298.42-7.69-93.42
Operating Margin--2,141.61--1,712.12-9,487.12-80.88-9,653.85-14,107.89
Net Margin--2,047.61-1,345.96-9,210.61-74.68-7,873.08-12,175.00
Shares Outstanding188.72184.76167.27130.1871.1571.1171.1171.01
Market Capitalization546.83502.06292.76116.0892.4423.4622.1766.30

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments69.6453.08105.83129.00187.8072.0376.7441.5087.13
Short Term Receivables0.000.000.000.000.000.141.130.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.732.873.762.382.682.671.942.771.46
Total Current Assets74.3755.94109.60131.38190.4874.8479.8144.2788.59
Net Property, Plant & Equipment11.8613.2314.6616.070.240.140.070.070.05
Total Investments and Advances64.7022.9119.567.553.560.000.000.000.00
Intangible Assets0.000.090.180.220.160.320.470.390.12
Other Assets0.000.000.030.040.100.630.502.920.69
Total Assets150.9392.17144.03155.27194.5475.9380.8447.6589.46
Short Term Debt Incl. Current Port. of LT Debt1.431.341.250.530.000.000.000.000.00
Accounts Payable1.963.193.701.957.135.453.263.762.03
Other Current Liabilities4.906.006.534.507.6716.627.285.094.00
Total Current Liabilities8.2910.5211.476.9914.8022.0610.538.846.02
Long Term Debt11.9913.4244.7616.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.0010.230.290.000.00
Total Liabilities20.2723.9456.2322.9914.8032.2910.828.846.02
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.001E-061E-061E-063E-068E-060.000.00
Common Equity130.6668.2387.80132.27179.7543.6370.0238.8183.44
Total Shareholders Equity130.6668.2387.80132.27179.7543.6370.0238.8183.44
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity130.6668.2387.80132.27179.7543.6370.0238.8183.44
Total Liabilities & Stockholders Equity150.9392.17144.03155.27194.5475.9380.8447.6589.46
Book Value Per Share1.000.961.241.882.550.661.281.573.39
Tangible Book Value Per Share1.000.961.241.872.550.661.271.563.39
Full-Time Employees232340445767595543
Price to Book Ratio2.660.872.250.921.263.483.241.542.61
Return on Assets-14.33-22.38-34.98-30.9788.62-103.38-94.11-75.82-90.97
Return on Equity-17.51-33.88-47.57-34.72107.30-142.60-111.11-85.04-97.65
Return on Invested Capital-12.21-32.38-39.49-36.5366.67-185.73-86.34-133.95-77.67
Quick Ratio8.975.329.5518.7912.873.397.585.0114.71
Current Ratio8.975.329.5518.7912.873.397.585.0114.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-43.11-17.41-26.43-52.34-54.17122.83-81.04-60.46-51.98
Depreciation0.080.270.611.601.380.240.310.260.14
Other Funds (Non Cash)-17.75-17.09-29.992.585.7912.357.335.187.07
Funds from Operations-60.78-34.23-55.81-48.17-47.00135.43-73.40-55.03-44.77
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.00-4.10-0.152.39-8.23-16.8121.823.94-0.79
Cash from Operating Activities-57.78-38.33-55.96-45.78-55.23118.61-51.58-51.09-45.56
Capital Expenditures0.000.00-0.16-0.14-1.42-0.19-0.39-0.24-0.35
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-141.70-49.8554.75-2.44-85.46-1.6335.04-29.80-5.01
Purchase of Investments-187.70-91.85-73.25-122.44-175.46-1.63-9.96-34.80-50.01
Sale Or Maturity of Investments46.0042.00128.00120.0090.000.0045.005.0045.00
Other Uses0.000.000.000.00-1.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-141.70-49.8554.59-2.58-87.88-1.8234.65-30.04-5.36
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock193.0475.210.620.540.180.9347.2486.540.29
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock193.0475.210.620.540.180.9347.2486.540.29
Proceedsfrom Stock Options192.3175.120.000.000.000.0046.7386.410.00
Issuance or Reduction of Debt, Net0.000.000.0030.000.000.000.000.000.00
Change in Long Term Debt0.000.000.0030.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.0030.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.02-0.160.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.02-0.160.000.00
Cash from Financing Activities193.0475.210.6230.540.180.9047.0786.540.29
Exchange Rate Effect--0.17-------
Net Change in Cash-6.80-13.15-0.74-17.83-142.93117.6930.145.41-50.64
Free Cash Flow-57.78-38.33-56.03-45.82-56.45118.43-51.71-51.15-45.59
Preferred Dividends (Cash Flow)-0.000.00-----0.00
Price to Free Cash Flow-----1.84---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments136.60117.22155.5269.6425.6038.35
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.366.404.624.733.223.74
Total Current Assets141.96123.62160.1574.3728.8242.09
Net Property, Plant & Equipment10.8411.1811.5211.8612.1912.50
Total Investments and Advances69.4497.1753.9764.7022.8422.84
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets222.24231.97225.63150.9363.8577.43
Short Term Debt Incl. Current Port. of LT Debt1.511.481.461.431.411.38
Accounts Payable5.864.078.881.961.713.95
Income Tax Payable0.130.180.17---
Other Current Liabilities4.364.245.244.903.683.59
Total Current Liabilities11.869.9815.758.296.808.92
Long Term Debt10.8411.2311.6111.9912.3512.71
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.870.870.000.000.000.00
Total Liabilities23.5722.0827.3620.2719.1521.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity198.67209.89198.27130.6644.7055.79
Total Shareholders Equity198.67209.89198.27130.6644.7055.79
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity198.67209.89198.27130.6644.7055.79
Total Liabilities & Stockholders Equity222.24231.97225.63150.9363.8577.43
Book Value Per Share1.051.141.191.000.630.78
Tangible Book Value Per Share1.051.141.191.000.630.78
Full-Time Employees---23--
Price to Book Ratio2.662.272.212.591.660.40
Return on Assets-30.14-22.30-15.73-14.33-43.64-39.05
Return on Equity-35.43-25.96-18.77-17.51-60.06-52.77
Return on Invested Capital-9.92-6.79-8.096.77-21.31-6.84
Quick Ratio11.9712.3910.178.974.244.72
Current Ratio11.9712.3910.178.974.244.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.78-15.01-16.999.66-12.16-4.68
Depreciation0.010.020.040.020.020.10
Other Funds (Non Cash)0.721.030.72-20.220.961.05
Funds from Operations-20.05-13.96-16.23-10.54-11.18-3.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.17-3.632.330.13-1.69-1.24
Cash from Operating Activities-15.88-17.59-13.90-10.41-12.87-4.77
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments11.15-86.745.95-72.065.0512.05
Purchase of Investments-3.85-102.74-4.05-77.06-4.95-4.95
Sale Or Maturity of Investments15.0016.0010.005.0010.0017.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.15-86.745.95-72.065.0512.05
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.2821.6088.9875.180.010.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.2821.6088.9875.180.010.00
Proceedsfrom Stock Options6.8421.5988.7675.120.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities7.2821.6088.9875.180.010.00
Exchange Rate Effect-0.07-0.00-0.12---
Net Change in Cash2.48-82.7480.91-7.46-7.807.28
Free Cash Flow-15.88-17.59-13.90-10.41-12.87-4.77

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 566.00K 2025: 7.25M
United States2024: 566.00K 2025: 7.25M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.03%18.1M180.9M1.70M
2026-10-159.99%18.1M180.9M1.58M
2026-09-3010.48%18.9M180.9M1.63M
2026-09-1511.69%21.2M180.9M2.21M
2026-08-3111.47%20.7M180.2M2.29M
2026-08-1412.01%21.6M180.2M2.24M
2026-07-3112.71%21.5M168.9M2.38M
2026-07-1513.05%22.0M168.9M2.47M
2026-06-3013.03%22.0M168.9M2.85M
2026-06-157.02%11.9M168.9M3.04M
2026-05-296.35%10.6M167.5M3.19M
2026-05-156.03%10.1M167.5M3.13M
2026-04-305.55%8.5M153.6M3.02M
2026-04-154.53%7.0M153.6M3.02M
2026-03-317.98%9.3M117.0M2.57M
2026-03-134.66%5.5M117.0M1.64M
2026-02-274.41%5.1M115.5M1.50M
2026-02-134.50%5.2M115.5M1.63M
2026-01-304.54%4.8M106.6M1.63M
2026-01-154.52%4.8M106.6M1.59M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.952.650.0017.7270.000.000.978-0.0100.000
call1.001.452.200.0010.5730.000.000.959-0.0110.000
call1.500.951.700.007.0890.000.000.893-0.0510.001
call2.000.451.200.904.9393.000.000.815-0.0510.001
call2.500.100.850.384.20481.000.000.715-0.0460.002
call5.000.000.050.052.4561.000.000.108-0.0110.001
call7.500.000.100.003.5770.000.000.083-0.0130.001
put0.500.000.050.007.6480.000.00-0.023-0.0100.000
put1.000.000.050.004.6680.000.00-0.042-0.0100.000
put1.500.000.750.0011.2110.000.00-0.107-0.0500.001
put2.000.000.750.189.26312.000.00-0.163-0.0530.001
put2.500.000.750.155.5861240.00-0.280-0.0460.002
put5.001.852.600.005.2140.000.00-0.892-0.0110.001
put7.504.205.200.007.2860.000.00-0.917-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-11SEC
2026-08-13SCHEDULE 13G/ASEC
2026-07-29SCHEDULE 13GSEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-083Initial statement of beneficial ownership of securities2026-07-06SEC
2026-07-088-KCurrent report2026-07-05SEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-173Initial statement of beneficial ownership of securities2026-06-15SEC
2026-06-118-KCurrent report2026-06-11SEC
2026-06-038-KCurrent report2026-05-29SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-27ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020029.29K2
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Jupiter Topco LLC11.11%
EVENTIDE ASSET MANAGEMENT, LLC6.33%
BlackRock, Inc.5.80%
RA CAPITAL MANAGEMENT, L.P.5.63%
Affinity Asset Advisors, LLC5.44%
STATE STREET CORP4.23%
VANGUARD CAPITAL MANAGEMENT LLC4.16%
ADAR1 Capital Management, LLC3.97%
BALYASNY ASSET MANAGEMENT L.P.3.60%
ADAGE CAPITAL PARTNERS GP, L.L.C.3.30%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.03%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.64%
iShares Russell 2000 ETF2.08%
Federated Hermes Kaufmann Small Cap Fund1.91%
VANGUARD EXTENDED MARKET INDEX FUND1.05%
Eventide Healthcare & Life Sciences Fund1.04%
Fidelity Small Cap Index Fund0.90%
iShares Russell 2000 Value ETF0.65%
VANGUARD RUSSELL 2000 INDEX FUND0.45%
Fidelity Extended Market Index Fund0.43%

OakChart. OVID. Cached 15 minutes.